Compare BIO-TECHNE Corp (TECH) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Consumer Staples Select Sector SPDR Fund — how do they compare? BIO-TECHNE Corp trades at $72.45 (market cap $11.36B), while Consumer Staples Select Sector SPDR Fund trades at $83.35 (market cap $13.50B). The key difference: Consumer Staples Select Sector SPDR Fund is the larger of the two by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Consumer Staples Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 63 Days and Consumer Staples Select Sector SPDR Fund for 72 Days on average.
| TECH | XLP | |
|---|---|---|
Market Cap | $11.36B | $13.50B |
Volume | 5,390,331 | 14,599,953 |
Sector | Health | — |
52-Week High | $72.61 | $90.00 |
52-Week Low | $43.31 | $75.61 |
Typical Hold Time | 63 Days | 72 Days |
Enterprise Value | $11.39B | — |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.47, down 0.08% on the day, near its 52-week high of $72.70 (Defense World, 2026-09-28). The stock shows a bullish technical trend with strong moving average signals. Recent shareholder approval of the acquisition by Merck KGaA at $73.00 per share (PRNewsWire, 2026-09-23) is a key catalyst. Q2 2026 earnings beat expectations with EPS of $0.52 versus $0.519 expected, though net income margin has declined from 25.09% in 2023 to 14.96% in 2026.
The pending acquisition offers a near-term upside to the current price, but high valuation ratios (P/E of 62.46, P/S of 9.36) pose a risk if the deal faces regulatory hurdles. Analyst consensus is mixed with 46% Buy and 54% Hold ratings. The stock presents a favorable risk-reward for investors seeking a takeover arbitrage opportunity, with the primary risk being deal failure.
XLP (Consumer Staples Select Sector SPDR ETF) trades at $83.21, up 1.85% with bullish technical signals from moving averages and oscillators. The ETF has gained 6.6% year-to-date, outperforming consumer discretionary stocks. Analyst consensus is strongly positive with 100% buy ratings. Recent news highlights XLP's defensive characteristics amid economic uncertainty and its competitive expense ratio advantage over peers.
The outlook remains favorable given XLP's defensive positioning in consumer staples, though rising interest rates pose a headwind. Investment opportunity lies in the ETF's stability during market volatility, while risks include persistent inflation pressures and potential consumer spending slowdown. The technical setup suggests continued upward momentum with support at $82-83 levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
